Martin Kleckner

Wireless-Health-Hub-M-KlecknerMr. Kleckner’s background comprises 26 years on senior level operations, general management, marketing and business development in the life sciences, oil & gas, cable television, counter-intelligence and aerospace. His current work encompasses guiding emerging and established companies with corporate planning and strategy, commercialization and business development, marketing, and public policy throughout Europe, Asia & the Americas.

He is a co-founder of, a Health 2.0 Internet company specializing in gastroesophageal reflux disease. He further provides commercialization advisory support to the National Institutes of Health, Drexel Foundation, and Coulter Foundation with regard to awarded grants plus “Go/No-Go” grant funding decisions. He was previously Chief Operations Officer for The Nicholas Conor Institute for Pediatric Cancer Research, Inc., a 501 (c) 3 not-for-profit enterprise specializing in the translation and advancement of new molecular biology (genomics and proteomics) diagnostics and treatments via foundation and corporate life science partnerships.

Previously he was Chief Executive Officer for U P Laboratories in San Diego for the development of proprietary synthetic peptides (excitation secretion uncoupling peptides) as an alternative to botulinum neurotoxin (BoTox®) for topical anti-aging/wrinkle inhibition and hyperhidrosis. Earlier he was Senior Vice President for Business Development at InSilicoMed, a start-up company providing bioengineering simulation tools for cardiology and ophthalmic therapy applications; Senior Vice President of Business Development and angel investor for RegeneMed, a company creating three dimensional (3D) engineered liver tissue for drug discovery and bio-artificial liver support; co-founder and Chief Business Officer for Salvino-Flex LLC wherein he managed the research and development of a chest tube insertion device, ultimately selling the company. He was also Director of Development for Science and Engineering Associates for the commercialization of a diagnostic technology applicable to cervical, ovarian and oral/pharyngeal cancers.

He has further served as healthcare economist for Roche, Respironics, Toshiba Medical, and Terumo Interventional while also teaching courses for General Electric at its Crotonville, New York campus. Previously he was Director of Venture Development/Contracts Executive with American Healthcare Systems serving in the starting group growing the company to $45 million in annual revenue eventually selling to Premier, Inc.

Mr. Kleckner’s education consists of an MBA from the University of California, Los Angeles (UCLA) Anderson School; a PhD in Public Policy from the University of California, Riverside; a certificate in public health from the University of California, San Diego (UCSD); and a Bachelor of Arts (BA) with concentrations in public policy and economics from Whittier College.